Brokerages Set NextCure, Inc. (NASDAQ:NXTC) Target Price at $23.00

NextCure, Inc. (NASDAQ:NXTC) has received an average rating of “Hold” from the five analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $23.00.

NXTC has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a report on Monday, April 27th. Zacks Research downgraded NextCure from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 6th.

NextCure Price Performance

NASDAQ:NXTC opened at $2.79 on Tuesday. The firm’s fifty day moving average price is $9.20 and its 200 day moving average price is $11.22. NextCure has a 1-year low of $2.65 and a 1-year high of $15.74. The firm has a market cap of $10.07 million, a price-to-earnings ratio of -0.16 and a beta of 1.31.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. As a group, analysts expect that NextCure will post -7.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NextCure

A number of hedge funds and other institutional investors have recently bought and sold shares of NXTC. Cable Car Capital LP lifted its holdings in NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the period. Geode Capital Management LLC lifted its holdings in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after acquiring an additional 3,636 shares during the period. Renaissance Technologies LLC lifted its holdings in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after acquiring an additional 5,300 shares during the period. Exome Asset Management LLC acquired a new stake in NextCure in the fourth quarter valued at $2,341,000. Finally, AWM Investment Company Inc. acquired a new stake in NextCure in the fourth quarter valued at $1,665,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.